Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Tumor-Agnostic 1

Conditions

Multiple Myeloma 2Neoplasms 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Remote Patient Monitoring × 90 days × Clear all
NCT06179888 2026-05-13

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Recruiting
78 enrolled
Plasma cell

Multiple Myeloma

NCT06145581 2026-04-13

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

Mayo Clinic

Phase NA Recruiting
25 enrolled
Plasma cell

Multiple Myeloma

NCT04913259 2026-03-03

TS-PAC

Institut Bergonié

Phase NA Active not recruiting
33 enrolled 8 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡